<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271114</url>
  </required_header>
  <id_info>
    <org_study_id>FISCAM AN-2010/28</org_study_id>
    <secondary_id>2010-024138-43</secondary_id>
    <nct_id>NCT01271114</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension</brief_title>
  <acronym>HYSATESS-p</acronym>
  <official_title>Hypertonic Saline and Terlipressin Linked To an Early Goal-Driven Protocol for Septic Shock or Sepsis-Associated Hypotension: A Pilot Trial (HYSATESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Ciudad Real</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General de Ciudad Real</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In hypotensive septic patients with controlled source, an hemodynamic management protocol
      including hypertonic saline (HS)and terlipressin improves MOD (Multiple Organ Dysfunction)
      Score by at least 3 points compared to the use of physiologic saline and norepinephrine.

      The appropriate design for this trial would be factorial. For the time being, will consider
      de intervention as a whole unit for this pilot study. In the future an appropriately sized
      factorial multicentric study shall be necessary.

      Other goals of the pilot study:

        1. HS restores preload parameters adequately

        2. HS associated with terlipressin normalizes blood pressure in septic shock

        3. HS associated with terlipressin maintains plasma sodium levels 130-155mEq/L

        4. There is an inverse relationship between plasma sodium and procalcitonin levels

        5. HS increases plasma levels of vasopressin (AVP)

        6. HS rises levels of cortisol but not of adrenocorticotropic hormone (ACTH)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment rate
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MOD (Multiple Organ Dysfunction) Score</measure>
    <time_frame>daily, as long as the patient stays in the ICU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertonic Saline restores IV fluid response parameters (Pulse Pressure Variation or Systolic Volume Variation) adequately</measure>
    <time_frame>First 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertonic Saline associated with terlipressin maintains plasma sodium levels 130-155mEq/L</measure>
    <time_frame>As long as Hypertonic saline plus terlipressin are in use and one week later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>There is an inverse relationship between plasma sodium and plasma procalcitonin levels measured by a negative Pearson coefficient</measure>
    <time_frame>As long as the patient stays in the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertonic Saline associated with terlipressin normalizes blood pressure in septic shock</measure>
    <time_frame>First 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertonic Saline boluses increases plasma levels of vasopressin (AVP)</measure>
    <time_frame>First week in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertonic Saline use rises levels of cortisol but not of adrenocorticotropic hormone (ACTH)</measure>
    <time_frame>First week in ICU</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis-associated Hypotension</condition>
  <arm_group>
    <arm_group_label>Hypertonic Saline and Terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline and norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline and Terlipressin</intervention_name>
    <description>Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg</description>
    <arm_group_label>Hypertonic Saline and Terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline and norepinephrine</intervention_name>
    <description>Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg</description>
    <arm_group_label>Normal Saline and norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Criteria of SIRS: at least 2 of 4:

               -  Temperature &gt; 38 °c or &lt; 36 ° C

               -  More than 90 bpm heart rate

               -  Respiratory rate more than 20rpm or PaCO2 less than 32 mm Hg or patient in
                  mechanical ventilation

               -  Less than 4000/ mm³ or more than 12000/mm³, or more than 10% leukocyte bands
                  (immature)

          -  Septic source known demonstrated (or at least of high probability) and controlled (if
             it is controllable)

          -  Hematocrit 25% or higher and/or hemoglobin 8 g/dL or higher. If necessary, transfuse
             RBCs to meet this criteria

          -  MAP less than 70 mm Hg. Note there is no requirement for adequate preload evidence

        Exclusion Criteria:

          -  Hypernatremia at base-line of 155 mEq/L or greater Hyponatremia at base-line less than
             130mEq / L

          -  Prior endocrine disease affecting to the adrenal-pituitary axis.

          -  Intracranial Hypertension, brain tumor, seizures, head trauma

          -  Coronary Artery Disease active over the past year; or evidence of &quot;myocardium at risk&quot;
             by exercise stress test, pharmacological or positive gammagraphy last year without
             intervention

          -  Pregnancy

          -  Liver disease Child C, End-Stage-Renal-Disease

          -  Under the age of 18

          -  Patients with order &quot;do not resuscitate&quot; or with minimal chances to survive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Pascual Ramírez</last_name>
    <role>Principal Investigator</role>
    <affiliation>HGCR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis COLLAR VIÑUELAS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>HGCR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Ciudad Real</investigator_affiliation>
    <investigator_full_name>Javier Pascual-Ramirez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

